Delivery Method: Electronic Mail Product: Drugs Recipient: Recipient Name Mr. Dennis P. Borrello Recipient Title President and CEO Ultra Seal Corporation 521 Main StreetNew Paltz, NY […]

Hello. In this presentation, I will discuss the Critical Path Innovation Meeting, otherwise known as CPIM,  program, including goals of the program, how to request a […]

Department of JusticeU.S. Attorney’s OfficeDistrict of Puerto Rico FOR IMMEDIATE RELEASEWednesday, September 25, 2024 HHS OIG and FDA are in charge of the investigation SAN JUAN, […]

BPC-157 503A September 29, 2023 Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to […]

For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment […]

[9/26/2024] FDA is alerting patients, caregivers, and health care professionals that Oxbryta (voxelotor) is being voluntarily withdrawn from the market by the manufacturer due to safety […]

[09-26-2024] The U.S. Food and Drug Administration is advising consumers not to purchase or use Amazy, a product promoted and sold for pain on various websites, including […]

[09-26-2024] The U.S. Food and Drug Administration is advising consumers not to purchase or use Ácido Hialurónico (or Acid Hyaluronic), a product promoted and sold for pain […]

Stop distributing unapproved drugs included in kits On September 20, 2024, FDA requested Azurity Pharmaceuticals Inc. stop distributing unapproved drugs marketed as “Unit-of-Use Prescription Compounding Kits,” […]